Fardad Soltani

Fardad Soltani

Auto-generated profile, based on publicly available information

Fardad Soltani

Division of Cardiovascular Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, University of Manchester

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 March 2023 in Journal of Cardiac Failure
Verified
Journal Article
Open access
FSFardad Soltani
Fardad Soltani
GLGavin A. Lewis
Gavin A. Lewis
ARAnna Rosala-Hallas
Anna Rosala-Hallas
SDSusanna Dodd
Susanna Dodd
ESErik B. Schelbert
Erik B. Schelbert
CMChristopher A Miller
Christopher A Miller
Medication adherence in patients with heart failure with preserved ejection fraction is unclear. This study sought to evaluate treatment adherence in the Pirfenidone in Patients with Heart Failure and Preserved Left Ventricular Ejection Fraction (PIROUETTE) trial. Adherence was evaluated through pill counts and diary cards. Univariable and multivariable regression models were used to assess the relationship between adherence and baseline characteristics. Instrumental variable regression was used to estimate the causal effect of pirfenidone treatment duration on myocardial fibrosis. Complete adherence data were available in 54 of 80 participants completing the trial. Mean adherence to study medication was 94.7% and 96.9% in the pirfenidone and placebo groups, respectively. Each additional day of treatment with pirfenidone resulted in a significant decrease in myocardial extracellular volume (-0.004%; 95% confidence interval: -0.007% to -0.001%; P = 0.007). Associations with adherence included older age, higher symptom burden, lower body weight, and smaller right ventricular size. Adherence to study medication in the PIROUETTE trial was very high among patients for whom complete adherence data were available. Importantly, each additional day of treatment reduced myocardial fibrosis. Potential predictors of adherence were identified. Implementation of improved methods for assessing adherence is required.

17 January 2024 in ESC Heart Failure
Verified
Journal Article
Open access
FSFardad Soltani
Fardad Soltani
JBJoshua Bradley
Joshua Bradley
ABAntonio Bonandi
Antonio Bonandi
NBNicholas Black
Nicholas Black
JFJohn P. Farrant
John P. Farrant
CMChristopher A Miller
Christopher A Miller
Aims: Population-wide, person-level, linked electronic health record data are increasingly used to estimate epidemiology, guide resource allocation, and identify events in clinical trials. The accuracy of data from NHS Digital (now part of NHS England) for identifying hospitalization for heart failure (HHF), a key HF standard, is not clear. This study aimed to evaluate the accuracy of NHS Digital data for identifying HHF. Methods and results: Patients experiencing at least one HHF, as determined by NHS Digital data, and age- and sex-matched patients not experiencing HHF, were identified from a prospective cohort study and underwent expert adjudication. Three code sets commonly used to identify HHF were applied to the data and compared with expert adjudication (I50: International Classification of Diseases-10 codes beginning I50; OIS: Clinical Commissioning Groups Outcomes Indicator Set; and NICOR: National Institute for Cardiovascular Outcomes Research, used as the basis for the National Heart Failure Audit in England and Wales). Five hundred four patients underwent expert adjudication, of which 10 (2%) were adjudicated to have experienced HHF. Specificity was high across all three code sets in the first diagnosis position {I50: 96.2% [95% confidence interval (CI) 94.1–97.7%]; NICOR: 93.3% [CI 90.8–95.4%]; OIS: 95.6% [CI 93.3–97.2%]} but decreased substantially as the number of diagnosis positions expanded. Sensitivity [40.0% (CI 12.2–73.8%)] and positive predictive value (PPV) [highest with I50: 17.4% (CI 8.1–33.6%)] were low in the first diagnosis position for all coding sets. PPV was higher for the National Heart Failure Audit criteria, albeit modestly [36.4% (CI 16.6–62.2%)]. Conclusions: NHS Digital data were not able to accurately identify HHF and should not be used in isolation for this purpose.

14 June 2025 in Advances in Rheumatology
Verified
Journal Article
Open access
PDF file
NBNicholas Black
Nicholas Black
JBJoshua Bradley
Joshua Bradley
FSFardad Soltani
Fardad Soltani
JFJohn P. Farrant
John P. Farrant
JNJosephine H. Naish
Josephine H. Naish
CMChristopher A Miller
Christopher A Miller
Background: Myocardial fibrosis is an important adverse prognostic marker, however; determinants of myocardial fibrosis in immune-mediated inflammatory diseases (IMIDs) remain poorly defined. We aimed to identify determinants of myocardial fibrosis in patients with IMIDs, as measured by cardiovascular magnetic resonance (CMR) extracellular volume (ECV). Methods: Cross-sectional study of 116 patients with IMIDs undergoing clinical CMR at Manchester University NHS Foundation Trust. IMIDs included rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis (SSc), ankylosing spondylitis, psoriatic arthritis and vasculitis. CMR included pre- and post-contrast T1 mapping to measure myocardial ECV, with same day blood sampling. Determinants of ECV were investigated with univariable and multivariable linear regression. Results: ECV varied significantly according to IMID diagnosis (ANOVA F statistic 2.80, P = 0.015); ECV was higher in patients with SSc compared to other IMIDs. Major determinants of ECV as a continuous variable were SSc, smoking and body mass index (BMI); regression coefficients 3.33 (95% confidence interval 0.82–5.84), 3.08 (0.73–5.43), and − 0.19 (-0.29 – -0.09) respectively, P < 0.01 (SSc, smoking and lower BMI were associated with increased ECV). Approximately a quarter of the variability in ECV could be explained by these predictors (optimism adjusted R 2 0.265). Conclusion: SSc is associated with a higher burden of myocardial fibrosis compared to other IMIDs. In patients with IMIDs, independent determinants of myocardial fibrosis were presence of SSc, smoking and BMI. Importantly, participants underwent CMR for clinical indications and may not be representative of IMID populations in the community.

5 March 2026 in European Journal of Heart Failure
Verified
Journal Article
Open access
FSFardad Soltani
Fardad Soltani
NBNicholas Black
Nicholas Black
JBJoshua Bradley
Joshua Bradley
LPLucy Priestner
Lucy Priestner
NKNaing Ko Ko
Naing Ko Ko
CMChristopher A Miller
Christopher A Miller
Aims: Heart failure with preserved ejection fraction (HFpEF) is a heterogeneous syndrome commonly hypothesized to comprise discrete subtypes. This study aimed to characterize HFpEF heterogeneity using advanced data science techniques applied to deeply phenotyped, multi-modal cohorts. Methods and Results: A total of 902 patients with HF and a left ventricular ejection fraction ≥50% were prospectively recruited and underwent detailed clinical, imaging, and genetic profiling. Clustering algorithms were first applied to derive discrete subgroups. To overcome rigid subgroup assignment, DDRTree was applied to map continuous phenotypic and outcome variation onto a two-dimensional tree. Genome-wide association studies (GWAS) identified variants associated with tree dimensions. Internal validation assessed stability, and external validation was conducted in a UK Biobank HFpEF cohort (n = 148). Sensitivity analyses included patients with mildly reduced ejection fraction (n = 1154). Logistic regression compared HFpEF with comorbidity-matched controls (n = 902). Whilst conventional clustering did not identify meaningful subgroups, DDRTree revealed a stable, interpretable tree structure, capturing continuous variation in cardiac structure and function, biomarkers and comorbidities. Over a median follow-up of 6.8 years, phenotypic complexes demonstrated differing risks of cardiovascular death, HF hospitalization, adverse renal outcome, and infection hospitalization. GWAS revealed a locus near CRACD associated with tree dimension one. Findings were reproducible in external and sensitivity analyses. A profile of cardiac and systemic characteristics that distinguish HFpEF from its associated comorbidities were identified. Conclusions: HFpEF risk and disease course reflect a variable interplay of pathophysiological processes in each individual. This study provides a biologically plausible framework to guide a more personalized approach to HFpEF.

28 January 2025 in BMJ Open
Verified
Journal Article
Open access
JBJo Bilak
Jo Bilak
ISIain Squire
Iain Squire
JWJoanne V Wormleighton
Joanne V Wormleighton
RBRachel L Brown
Rachel L Brown
MHMichelle Hadjiconstantinou
Michelle Hadjiconstantinou
GMGerry P McCann
Gerry P McCann
Introduction: Heart failure with preserved ejection fraction (HFpEF) is characterised by severe exercise intolerance, particularly in those living with obesity. Low-energy meal-replacement plans (MRPs) have shown significant weight loss and potential cardiac remodelling benefits. This pragmatic randomised trial aims to evaluate the efficacy of MRP-directed weight loss on exercise intolerance, symptoms, quality of life and cardiovascular remodelling in a multiethnic cohort with obesity and HFpEF. Methods and analysis: Prospective multicentre, open-label, blinded endpoint randomised controlled trial comparing low-energy MRP with guideline-driven care plus health coaching. Participants (n=110, age ≥18 years) with HFpEF and clinical stability for at least 3 months will be randomised to receive either MRP (810 kcal/day) or guideline-driven care for 12 weeks. Randomisation is stratified by sex, ethnicity, and baseline Sodium Glucose Cotransporter-2 inhibitor (SGLT2-i) use, using the electronic database RedCap with allocation concealment. Key exclusion criteria include severe valvular, lung or renal disease, infiltrative cardiomyopathies, symptomatic biliary disease or history of an eating disorder. Participants will undergo glycometabolic profiling, echocardiography, MRI for cardiovascular structure and function, body composition analysis (including visceral and subcutaneous adiposity quantification), Kansas City Cardiomyopathy Questionnaire (KCCQ) and Six-Minute Walk Test (6MWT), at baseline and 12 weeks. An optional 24-week assessment will include non-contrast CMR, 6MWT, KCCQ score. Optional substudies include a qualitative study assessing participants’ experiences and barriers to adopting MRP, and skeletal muscle imaging and cardiac energetics using 31Phosphorus MR spectroscopy. Statistical analysis: Complete case analysis will be conducted with adjustment for baseline randomisation factors including sex, ethnicity and baseline SGLT2-i use. The primary outcome is the change in distance walked during the 6MWT. The primary imaging endpoint is the change in left atrial volume indexed to height on cardiac MRI. Key secondary endpoints include symptoms and quality of life measured by the KCCQ score. Ethics and dissemination: The Health Research Authority Ethics Committee (REC reference 22/EM/0215) has approved the study. The findings of this study will be published in peer-reviewed journals. Trial registration number: NCT05887271 .

12 June 2025 in medRxiv
Verified
Preprint
Open access
PDF file
SBSamuel Brown
Samuel Brown
FSFardad Soltani
Fardad Soltani
JWJack Wu
Jack Wu
MRMatthew Ryan
Matthew Ryan
BBBrett S Bernstein
Brett S Bernstein
KOKevin O'Gallagher
Kevin O'Gallagher
Background Heart failure with preserved ejection fraction is challenging to diagnose, precluding the initiation of prognostic medications. A deeper understanding of HFpEF phenotypes and trajectories could address this, however previous studies analyzed trial cohorts, limiting generalizability. Here we apply artificial intelligence (AI) algorithms to longitudinal electronic health record data (EHR) to characterize reproducible real-world HFpEF phenogroups. Methods We applied natural language processing (NLP) to extract structured and unstructured data from EHRs at a multi-site hospital network, including comorbidities, echocardiographic measurements, and all-cause mortality outcomes. HFpEF cases were identified by applying contemporaneous guideline-directed criteria. Phenogroups were derived at the first documented mention of ‘heart failure’ using latent class analysis, then reassigned annually to quantify the frequency and directionality of transitions. External validation was performed at an independent hospital network. Results We identified 2,223 patients (median age 75 years; 60% female) meeting HFpEF diagnostic criteria, with a median follow-up of 4 years. A clinician-recorded HFpEF diagnosis was present for only 10.4%. Four phenogroups were identified: Elderly-Atrial Dysfunction (32%), Cardio-Renal-Metabolic (23%), Obesity-Predominant (24%), and Young-Low Comorbidity (22%). The Young-Low Comorbidity group had the lowest rate of clinician-assigned HFpEF diagnosis (3%), and more than half of patients transitioned phenogroups within five years, suggesting this may represent an early-stage HFpEF phenotype. By contrast, Elderly-Atrial Dysfunction and Cardio-Renal-Metabolic groups displayed stable group membership (<10% transitioned), with high mortality rates (adjusted hazard ratio = 1.30 [1.02–1.67] and 1.49 [1.18–1.87] respectively). Phenogroup reproducibility was validated externally (n=3,349), demonstrating consistent clinical features and survival trends. Conclusion AI-enabled phenotyping of real-world data identified reproducible, prognostically significant HFpEF phenogroups. The identification of an underrecognized, early-stage subgroup underscores a critical opportunity for earlier diagnosis and targeted intervention to alter the clinical trajectory. What is new?Heart failure with preserved ejection fraction (HFpEF), as a heterogenous syndrome, can be characterized into four reproducible phenogroups, including an early-HFpEF phenotype. What are the clinical implications?Future research could build on implementation of scalable, EHR-enabled diagnostic strategies for early HFpEF detection. Longitudinal studies examining the impact of intervention on early phenogroups may provide valuable insights into modifying disease progression.